Alcon AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0432492467
CHF
63.24
0.24 (0.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Alcon AG stock-summary
stock-summary
Alcon AG
Pharmaceuticals & Biotechnology
Alcon AG is a Switzerland-based company specialized in the medical industry. The Company operates mainly as an eye care device company. Alcon AG reports its activities into two segments: Surgical and Vision Care. The surgical segment provides a line of ophthalmic surgical products that enable surgeons to achieve accurate results. Its surgical portfolio includes technologies and devices for cataract, retinal, refractive surgery, as well as advanced technology intraocular lenses (ATIOLs) to treat cataracts and refractive errors, such as presbyopia and astigmatism. The surgical segment also includes advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery. The Vision Care segment manufactures contact lenses and lens care products, such as products for dry eye, contact lens care, ocular allergies, as well as ocular vitamins and redness relievers. The Company also offers continuing education for eye care professionals.
Company Coordinates stock-summary
Company Details
Rue Louis-d'Affry 6 , FRIBOURG None : 1701
stock-summary
Tel: 41 589 112110
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 9 Schemes (2.64%)

Foreign Institutions

Held by 1141 Foreign Institutions (45.29%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. F. Michael Ball
Chairman of the Board
Mr. David Endicott
Chief Executive Officer, Director
Mr. D. Keith Grossman
Vice Chairman of the Board, Senior Independent Director
Dr. Arthur Cummings
Director
Ms. Lynn Bleil
Independent Director
Mr. Thomas Glanzmann
Independent Director
Mr. Scott Maw
Independent Director
Ms. Karen May
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2,144 Million
(Quarterly Results - Jun 2025)
Net Profit:
145 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 31,751 Million ()

stock-summary
P/E

30.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.06%

stock-summary
Debt Equity

0.18

stock-summary
Return on Equity

5.48%

stock-summary
Price to Book

1.81